New Data Supports the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Reducing Influenza-Related Hospitalizations and Healthcare Costs in Older Adults
Retrieved on:
Tuesday, December 7, 2021
RWE, Risk, Influenza vaccine, Population, Hospital, Disease, CSL, Haemophilia, European Scientific Cooperative on Phytotherapy, Economy, VAERS, Vaccine, CSL Behring, Antibody, Muscle weakness, Allergy, World, Event-driven architecture, Health, Influenza, Patient, Life expectancy, Selection bias, ASX, MF59, Conference, CDC, World Health Organization, Pablo de Olavide University, R, Season, Ageing, Society, FDA, Vaccination, TIV, Guillain–Barré syndrome, Degenerative disease, Research, Biotechnology, Immune system, MD, Immunodeficiency, Neve Ativ, WHO, Health insurance, Pharmaceutical industry, Dietary supplement
Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.
Key Points:
- Individual study limitations may include: retrospective analyses, a potential lack of laboratory confirmed influenza, and varying data sources.
- As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
- FLUAD (Influenza Vaccine, Adjuvanted) and FLUAD QUADRIVALENT (Influenza Vaccine, Adjuvanted)
What are FLUAD and FLUAD QUADRIVALENT? - To learn more, talk about FLUAD and/or FLUAD QUADRIVALENT with your healthcare provider or pharmacist.